Barcelona - Biocat

BarcelonaThe BioRegion of Catalonia

An expanding life sciences and healthcare startup ecosystem, based on world-class science, in a great city.

Rapid investment growth in life sciences startups

2016-2020

x41/week

A new company is created every week

+€225MInvestment in life

sciences and healthcare startups in 2020

Source: Biocat.*Private investment = Venture Capital, Private Equity, Stock Market, Crowdequity.

Investment growthin the last 5 years

(over the previous period)

2011-20150

100

200

300

400

500

600

Private investment*

Grants

Digital Health: A rapidly emerging subsector

2019-2021YTD*

X7X6Digital Health

startups in the last 10 years

+€34MInvestment in Digital Health startups in 2020

Source: Biocat.*2021YTD = April, 2021.

Investment growthin the last 5 years

(2016-2020)

2016-20180

20

40

60

80

100

Total Funding

(2011-2020)

Source: Crunchbase, report based on Seed, Venture Series, Angel, Crowdequity and Private Equity funding only.

A greatinvestment opportunity

Total VC/PE investment ($M) in emerging life sciences and healthcare startups (2016-2020)

3.3x

But the growth has only started

RECENT FOREIGN INVESTORS

of all investment in VC/PE rounds include foreign firms

57% from Europe (excl. Spain)30% from North America9% from Asia4% Other

A highly internationalized investment ecosystem

foreign VC/PE firmsinvesting in Barcelona startups73

Cumulative number of foreign investorsin life sciences and healthcare startups

Source: Biocat.

62%0

10

20

30

40

50

60

2015 2020

70

Find all angel investors, venture capital and private equity firms at: http://www.catalanlifesciences.com/

€700m Raised by specialised firms in the BioRegion,available for co-investment in the life sciences and healthcare

Source: Biocat.

Barcelona, home to specialized investors

OPEN FUNDS

€5-15m invested

Source: Biocat. Investments between 2015 and 2020, both included.

A diverse life sciences and healthcare startuplandscape

Biotechnology€30-150m invested

€15-30m invested

€1-5m invested

€5-15m invested

Medical Technology€30-150m invested

€1-5m invested

€5-15m invested

Digital Health

€1-5m invested

€30-150m invested

€15-30m invested

+200active companies

A booming Digital Health ecosystem

x2(2014-2019)

Source: Biocat. Illustrative representation. Relevant companies may not have been detected. Please contact us if you would like your company registered at http://www.catalanlifesciences.com/.

Source: Barcelona & Catalonia Start-up Hub (ACCIO) and Dealroom

5th Amsterdam4th Stockholm3rd Barcelona2nd Berlin1st Paris

3rd

EU TECH HUBby funding rounds for startups(all tech sectors, 2016-2020)

+1,700 startups(all sectors) +500 in Biotech, Medtech and Digital Health

#4 Berlin

#1 London

#5 BARCELONA

#7 Paris

#8 Amsterdam

Barcelona,

5th most invested city in Digital Health in Europe amid pandemic (2020–April 2021)

Source: Crunchbase, report based on Angel, Seed and Venture Capital Series funding only.

#2 Stockholm

#3 Oxford

#6 Copenhagen

#9 Marseille

#10 Oulu

+ US$ 100 M

US$ 50-100 M

US$ 30-50 M

Source: Startup Heatmap Europe, 2021.

Madrid

BARCELONA

Lisbon

London

Dublin Amsterdam Berlin

ViennaMunichZurich

Paris

Milan

Barcelona,

2nd most EU attractive city for startup founders

Source: Global Cities Investment Monitor - FDi Markets Database, 2018 and FDi Markets Magazine, 2019.

in the world by number of

international investments in R&D4th

TOP REGIONFinancial Times’ Southern Europe’s

for foreign investment

An opportunity to invest in world-class life sciences research & startups

Source: Nature Index, 2020.

8th Lausanne7th Oxford

6th Munich5th Berlin

4th Cambridge

10th Madrid9th Barcelona

3rd Zürich2nd Londonc

SCIENCE CITIES IN EUROPE,Nature Index

40th in the world

1st Paris

11th Stockholm12th Copenhaguen

13th Vienna14th Heidelberg

15th Amsterdam

With leading research centers, companies, hospitals and universities, Catalonia produces high quality life sciences and healthcare research at a large volume

Source: Scopus (Elsevier), SCIMAGO, SIRIS Academic. [Population] BEL=11,6M SWE=10M AUT= 9M CAT=7,5M DNK=5,8M FIN=5,5M IRL=4,9M

Source: CORDIS, UNiCS (SIRIS Academic), Biocat.

Catalan institutions and companies are very competitive in attracting EU funding, which supports the best research and innovation in Europe.

[Population] BEL=11,6M SWE=10M AUT= 9M CAT=7,5M DNK=5,8M FIN=5,5M IRL=4,9M

In 2020, 71% of Spain’s new ERC Advanced Grants have come to Catalonia.

Catalonia hosts 113 ERC grantees in the life sciences and healthcare, one of the highest ratios in Europe.The European Research Council (ERC) provides Europe’s most prestigiousand well-funded research grants.

Catalan institutions run excellent translational research, advancing rapidly towards commercialisation 1st

3rd

2nd CATALONIA

4th

5th

6th

7th

BELGIUM

SWEDEN

FINLAND

IRELAND

AUSTRIA

DENMARK

ERC PoC grants in the life sciences and healthcare

TRANS-LATIONAL RESEARCH

PROOF OF CONCEPT

BUSINESSFORMATION

/ LICENSING

BUSINESSGROWTH

(26)

The ERC Proof of Concept provides funding to bring ideas with commercial potential to a pre-demonstration stage, de-risking new technologies to commercial partners and investors.

Source: CORDIS, SIRIS Academic.

(15)

(13)

(11)

(10)

(9)

(6)

+400

Source: Biocat.

Synthetic biology

3D&Bio Printing

RNA Therapies

Genomics

Immunotherapies

deep tech companies

Biotech

Talented founders, with extensive pharma, clinical and research expertise

Digital Therapeutics

Telehealth

Bioinformatics

Digital Health

Big Data & Analytics

IoT

AR/VR

Artificial Intelligence

Blockchain

CS*/ICT

Electronics

Photonics

Advanced Materials

Robotics

Nanotechnology

KETs**

*Computer Science **Key Enabling Technologies

Source: Biocat.

A dynamic product pipelineBioRegion companies have 41 drugs and therapies in clinical development, covering a wide range of therapeutic areas.

In a world-class environment for clinical research

Source: Clinicaltrials.gov, SIRIS Academic.

Top pharma companies developing clinical trials in Catalonia

Number of active clinical trials

#13 worldwide#7 in the EU

Barcelona Supercomputing Center Alba SynchrotronNational Center

for Genomic AnalysisFully-equipped science and

business parks

And the best supporting research infrastructures

The right time to invest

x4 VC/PE investment growthin the last 5 years(over the previous period)

World-class life sciences research and startups

A great investment opportunityin Barcelona life sciences and healthcare startups

Source: ACCIO. More information: http://catalonia.com/.content/documents/RDIncentives_tcm213-241073.pdf

Generous tax incentives

Up to

59%for R&D

expenses

CORPORATE TAX EXEMPTION

Bonuses of

40%for R&D staff

SOCIAL SECURITY

Up to

60%of licensing

income exempted

PATENT BOX

Flat rate at

24%during the first

6 years

PERSONAL INCOME TAX FOR NON-RESIDENTS

● Accelerated introduction to local business practices and regulations (tax, corporate, labor, immigration law)

● Company incorporation, permits and paperwork

● Financing and incentives

Contact point: comunicacio@biocat.cat

Tailored support for foreign investors

● Site selection and temporary spaces

● Talent recruitment

● Reliable suppliers and business partners

● Networking

Investment support services:

Browse and explore investment opportunities

http://www.catalanlifesciences.com/

Catalan Life Sciences Database

LS&H multinationals - Innovation centers - Map of main actors

[Annexes]

Ecosystem overview

BiotechAbility PharmaMinoryx TherapeuticsOna TherapeuticsPeptomycPulmobiotics

MedtechAnaconda BiomedGlycardial DiagnosticsSTAT-DX

Digital HealthMediktorPsiousQMENTA

Selected case studies

A Europeanlife sciences and healthcare

business hub

Source: Biocat

Innovation centersrecently set up in Barcelona

Source: Biocat

(2018-20)

Map of main actorsA rich ecosystem,at a walking distance

Source: Biocat

FOUNDED: 2009

BiotechnologySECTOR:

OncologyEXPERTISE / SPECIALITY / FOCUS:

Clinical Phase IISTAGE:

Founders: Maribel Bergés Fraile (CEO)

Institutions: Autonomous University of Barcelona (UAB)

2010: Seed Round (€1.5m; Founders)

2012: pre-Series A (€1m; Inveready, Genoma España)

2019: Series A (€3.5m; Inveready, Everis)

2020: SME Instrument II (€2.5m; European Commission)European Investment Bank (€2.5m)

Developing advanced cancer therapies that are based upon autophagy, suitable as monotherapy or as first-line therapy.

1 worldwide patentINTELLECTUAL PROPERTY

FOUNDED: 2011

BiotechnologySECTOR:

Orphan CNS DiseasesEXPERTISE / SPECIALITY / FOCUS:

Clinical Phase IIISTAGE:

Founders: Joan Aymamí & Xavier Barril

Institutions: University of Barcelona (UB)Institute of Research and Advanced Studies (ICREA)

2013: Series A (€1.5m; Caixa Capital Risc, Inveready, Mineco, Acció)

2015: Series B (€20m; Ysios, Kurma partners, Roche Ventures, Chiesi Ventures, Indivest partners, Caixa Capital Risc, HealthEquity, Sanfilippo foundation)

2018: Series B II (€22m; Fund+, Federal holding and investment group, Société Régionale d’investissement, Sambrinvest)SME Instrument II (€3.1m, European Commission)

Developing new therapies with an unique mechanism of action for rare central nervous system diseases of genetic origin.

FOUNDED: 2019

BiotechnologySECTOR:

OncologyEXPERTISE / SPECIALITY / FOCUS:

Founders: Valerie Vanhooren (CEO) & Salvador Aznar (CSO)

Institutions: Institute for Research in Biomedicine (IRB) Institute of Research and Advanced Studies (ICREA)

PreclinicalSTAGE:

2019: Seed round (€1.5m; Asabys Partners )

2020: Serie A (€30m, Asabys Partners, Alta Life Sciences, Bpifrance Fund+, Ysios Capital)

Developing specialized therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism.

FOUNDED: 2014

BiotechnologySECTOR:

OncologyEXPERTISE / SPECIALITY / FOCUS:

PreclinicalSTAGE:

Founders: Laura Soucek (CEO) & Marie-Eve Beaulieu

Institutions: Vall d’Hebron Institute of Oncology (VHIO) Institute of Research and Advanced Studies (ICREA)

2016: Seed Round (€1m; HealthEquity) SME Instrument I (€50k; European Commission, )

2017: Series A (€4m; Alta LS, HealthEquity)

2019: SME Instrument II (€2.2m; European Commission)

2020: Looking for Series B to finish clinical phase I/II

Developing Omomyc, a new generation of cell penetrating peptides targeting the Myc oncoprotein against a wide range of tumors.

4 worldwide patentsINTELLECTUAL PROPERTY

FOUNDED: 2020

BiotechnologySECTOR:

Infectious DiseasesEXPERTISE / SPECIALITY / FOCUS:

PreclinicalSTAGE:

Founders: Maria Lluch (CSO) & Luis Serrano (Advisor)

Institutions: Centre of Genomic Regulation (CRG)

2020: Seed round (€2m; Invivo Ventures)

Developing a novel biotherapeutic platform able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner.

FOUNDED: 2015

Medical TechnologySECTOR:

CardiovascularEXPERTISE / SPECIALITY / FOCUS:

Clinical ValidationSTAGE:

Founders: Ofir Arad, Marc Ribó

2017: Series A (€15m; Ysios, Omega funds, Innogest, Banc Sabadell)

2018: EIT Health Headstart Funding

2020: Series B (Asabys, Banc Sabadell, Innogest, Omega funds)

Developing next generation catheters to perform mechanical thrombectomies safely and efficiently.

FOUNDED: 2017

Medical TechnologySECTOR:

CardiovascularEXPERTISE / SPECIALITY / FOCUS:

Clinical ValidationSTAGE:

Founders: Judit Cubero (CEO) & Lina Badimon (CSO)

Institutions: Catalan Institute of Cardiovascular Sciences (ICCC)Spanish National Research Council (CSIC)

2017: Series A (€2.4m; Caixa Capital Risc, Healthequity)

2018: SME Instrument I & EIT Health Headstart funding (European Commission, €490k)

2019: SME Instrument II (1.9M€; European Commission)

Developing a novel in vitro diagnostic device for the early diagnosis of cardiac ischemic events to reduce the impact of the disease on patients' life.

FOUNDED: 2010

Medical TechnologySECTOR:

DiagnosticsEXPERTISE / SPECIALITY / FOCUS:

Founders: Jordi Carrera, Rafel Bru

2011: Series A (€2m, Ysios, Axis)

2013: Series B (€17m; Kurma, Indivest, Boehringer venture, Caixa Capital Risc, Ysios, axis)

2016: Series B II (€29.1m; Glide, Ysios, Kurma, Caixa Capital Risc; Boehringer, Axis, Indivest, Siemens, Philips)

2017: European Investment Bank (€20m)

2017: Exit (€154m; Qiagen)

Developing and manufacturing molecular and immunoassay diagnostics systems for decentralized clinical testing.

FOUNDED: 2011

Digital HealthSECTOR:

TelehealthEXPERTISE / SPECIALITY / FOCUS:

Class I Certified Medical Device

STAGE:

Founders:Cristian Pascual (CEO), Dr. Oscar Garcia (CMO), Roger Forcada (CTO) & Josep Carbó (CBDO)

2011: Seed Round (€1.6m, Local B.A.)

2018: Series A (€3m; Alta, Castel, Naos)

2020: Looking for series B

Developing an AI-based medical assistant that relates patient’s symptoms with possible conditions, giving recommendations on what to do next.

FOUNDED: 2013

Digital HealthSECTOR:

Mental and behavioural disorders

EXPERTISE / SPECIALITY / FOCUS:

Validation TrialsSTAGE:

Founders: Xavier Palomer (CEO) & Victor García (CTO)

2015: Seed Round (€1m; Rothenberg, Caixa Capital Risc)

2016: SME Instrument II (European Commission, €600k)

2019: Series A (€8m; Asabys, Caixa Capital Risc, CG Health Ventures, Bstartup)

Developing virtual reality-based solutions for therapeutic use in the clinical practice of mental health conditions.

FOUNDED: 2013

Digital HealthSECTOR:

Drug DevelopmentEXPERTISE / SPECIALITY / FOCUS:

Founders:Landon McKenna (CCO), Vesna Prchkovska (COO) & Paulo Rodrigues (CTO)

2014: Seed round (€160k; crowdfunding)

2017: Series A (€2.7m; Business Angels) & SME Instrument I (€50k)

2018: SME Instrument II (€300k)

2020: Series A II (€1.4m; crowdfunding)

Developing medical image processing algorithms through AI, in order to accelerate the development of new therapies for neurological diseases.

BarcelonaThe BioRegion of Catalonia

www.bioregioncatalonia.com #BioRegionCatalonia